ArticleJournal of nanobiotechnology2025
Dual-site spatiotemporal and simultaneous inhibition on PIN1 via arsenic-retinoic albumin nanoparticles enables synergistic oncotherapy.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- D-limonene ameliorates metabolic dysfunction-associated steatotic liver disease by inhibiting the PPARγ/SCD-1 pathway and improving lipid metabolism disorders.Frontiers in pharmacology · 2026Article
- AS1411-functionalized albumin nanoparticles for nucleolin-targeted realgar delivery and therapy in triple-negative breast cancer.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (Pin1) is a master regulator of oncogenic signaling, uniquely catalyzing the isomerization of phosphorylated Ser/Thr-Pro motifs to drive malignant transformation, proliferation, and metastasis. Despite its central role in tumorigenesis, effective therapeutic targeting of Pin1 remains unmet. Current inhibitors such as all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) show limited efficacy due to their insufficient potency as standalone agents. Here, we report the rational design of dual-drug-conjugated human serum albumin nanoparticles (ATRA-ATO-NPs) that enable dual-site, spatiotemporal, and simultaneous inhibition of Pin1. These engineered nanoparticles exhibit uniform morphology, sustained co-release kinetics, and enhanced tumor accumulation via improved permeability and retention. In vitro, ATRA-ATO-NPs achieved synergistic inhibition of hepatocellular carcinoma proliferation and migration, significantly outperforming free or co-administered drugs. In vivo, ATRA-ATO-NPs produced superior tumor suppression and reduced lung metastasis in murine models without inducing hematologic or organ toxicity. Mechanistically, proteomic and pathway enrichment analyses revealed broader and deeper inhibition of Pin1-regulated oncogenic and metabolic networks─including Wnt/β-catenin, NF-κB, and CDK signaling─compared to either drug alone. Collectively, ATRA-ATO-NPs offer a mechanistically targeted, systemically safe, and highly effective strategy for advanced oncotherapy through dual-site spatiotemporal and simultaneous Pin1 inhibition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.